Long-term cryopreserved umbilical cord derived mesenchymal stem cells: A study on their safety

Main Article Content

Kyoko Baba Yoshika Sugimoto Kazuno Moriyama Kenichi Kumazawa Takayuki Sugimoto Yasuharu Yamazaki Akira Takeda

Abstract

Background: In recent years, mesenchymal stem cells have gained attention in the field of regenerative medicine. While mesenchymal stem cells derived from adipose tissue and bone marrow are well-studied, obtaining sufficient tissue from neonates or infants poses significant challenges. Umbilical cord-derived mesenchymal stem cells are a promising alternative source, as they can be harvested non-invasively and in large quantities with minimal ethical concerns. This study aims to evaluate the safety of long-term cryopreserved umbilical cord-derived mesenchymal stem cells and explore their potential for clinical applications in regenerative medicine.


Methods: Umbilical cord-derived mesenchymal stem cells were cryopreserved for periods ranging from 4 years and 5 months to 5 years and 9 months. After thawing, the following assessments were performed:


  1. Morphological changes: Cell morphology was observed under a light microscope before and after cryopreservation.

  2. Multipotency evaluation: Osteogenic and adipogenic differentiation potentials were assessed to confirm MSC characteristics.

  3. Chromosomal stability: G-band staining and Spectral Karyotyping were used to identify numerical and structural chromosomal abnormalities.

  4. Tumorigenic potential: Real-time PCR was conducted to measure the expression of telomerase reverse transcriptase, a tumorigenic marker.

Results: No significant morphological differences were observed before and after cryopreservation. Both osteogenic and adipogenic differentiation potentials were maintained, confirming the multipotency of the cells. Chromosomal abnormalities were found in 4 out of 168 cells using G-banding, but no abnormalities were detected with Spectral Karyotyping. Telomerase reverse transcriptase gene expression was low, indicating a low risk of tumorigenicity.


Conclusion: Long-term cryopreserved umbilical cord-derived mesenchymal stem cells maintain their safety in terms of morphology and function, showing promise as autologous graft material for regenerative medicine. However, further safety evaluations, particularly concerning chromosomal abnormalities, are essential before clinical application.

Keywords: Umbilical cord-derived mesenchymal stem cells, Long-term cryopreservation, safety evaluation, regenerative medicine

Article Details

How to Cite
BABA, Kyoko et al. Long-term cryopreserved umbilical cord derived mesenchymal stem cells: A study on their safety. Medical Research Archives, [S.l.], v. 12, n. 10, oct. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5944>. Date accessed: 03 dec. 2024. doi: https://doi.org/10.18103/mra.v12i10.5944.
Section
Research Articles

References

1. Behnia H, Khojasteh A, Soleimani M, Tehranchi A, Atashi A. Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: A preliminary report. J Craniomaxillofac Surg. 2012;40(2):7.
2. Plachokova AS, van den Dolder J, van den Beucken JJ, Jansen JA. Bone regenerative properties of rat, goat and human platelet-rich plasma. Int J Oral Maxillofac Surg. 2009;38(8):861-869.
3. Lee JY, Nam H, Park YJ, et al. The effects of platelet-rich plasma derived from human umbilical cord blood on the osteogenic differentiation of human dental stem cells. In Vitro Cell Dev Biol Anim. 2011;47(2):157-164.
4. Qi Y, Niu L, Zhao T, et al. Combining mesenchymal stem cell sheets with platelet-rich plasma gel/calcium phosphate particles: A novel strategy to promote bone regeneration. Stem Cell Res Ther. 2015;6:256.
5. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: A source of mesenchymal progenitors. Stem Cells. 2005;23:220-229.
6. Pivoriūnas A, Bernotiene E, Unguryte A, et al. Isolation and differentiation of mesenchymal stem-like cells from human umbilical cord vein endothelium and subendothelium. Biologija. 2006;2:99-103.
7. Kern S, Eichler H, Stoeve J, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood or adipose tissue. Stem Cells. 2006;24(5):1294-1301.
8. Chen M, Peng J, Xie Q, et al. Mesenchymal stem cells alleviate moderate-to-severe psoriasis by reducing the production of type I interferon (IFN-I) by plasmacytoid dendritic cells (pDCs). Stem Cells Int. 2019;2019:6961052.
9. Lin Y, Wang H, Jiang C, et al. Effects of different concentrations of human umbilical cord mesenchymal stem cells to ameliorate psoriasis-like skin lesions in BALB/c mice. Ann Transl Med. 2022;10(2):86.
10. Wang Z, Hu Y, Wang X, et al. Comparative analysis of the therapeutic effects of fresh and cryopreserved human umbilical cord-derived mesenchymal stem cells in the treatment of psoriasis. Stem Cell Rev Rep. 2023;19:1922-1936.
11. Ahn H, Lee SY, Jung WJ, Pi J, Lee KH. Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report. World J Clin Cases. 2021;9:6798-6803.
12. Ohgushi H, Kitamura S, Kotobuki N, et al. Clinical application of marrow mesenchymal stem cells for hard tissue repair. Yonsei Med J. 2004;45:61-67.
13. Ishiguro M, Yamazaki Y, Baba K, et al. Assessment of the osteogenic potential of maxilla-derived mesenchymal stromal cells and the utilization of serum-free medium for culture thereof. Kitasato Med J. 2014;44:84-94.
14. Aoyagi K, Yamazaki Y, Matsuo A, et al. Significance of CD271 in bone marrow mesenchymal stem cells: Changes by cryopreservation. J Craniofac Surg. 2010;21(3):666-678.
15. Zhang M, Zhao Y, Wang L, et al. Study of the biological characteristics of human umbilical cord mesenchymal stem cells after long-time cryopreservation. Cell Tissue Bank. 2022;23:739-752.
16. Baba K, Yamazaki Y, Ikemoto S, et al. Osteogenic potential of human umbilical cord-derived mesenchymal stromal cells cultured with umbilical cord blood-derived autoserum. J Craniomaxillofac Surg. 2012;40:768-772.
17. Ogata S, Ogihara Y, Nomoto K, et al. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from the addition of methylprednisolone. Pediatr Res. 2009;19:577-584.
18. Baba K, Yamazaki Y, Ishiguro M, et al. Osteogenic potential of human umbilical cord-derived mesenchymal stromal cells cultured with umbilical cord blood-derived fibrin: A preliminary study. J Craniomaxillofac Surg. 2013;41:775-782.
19. Badowski M, Muise A, Harris DT. Mixed effects of long-term frozen storage on cord tissue stem cells. Cytotherapy. 2014;16(9):1313-1321.
20. Shimazu T, Mori Y, Takahashi A, et al. Serum- and xeno-free cryopreservation of human umbilical cord tissue as mesenchymal stromal cell source. Cytotherapy. 2015;17(5):593-600.
21.Müller L, Tunger A, Wobus M, et al. Immunomodulatory properties of mesenchymal stromal cells: An update. Front Cell Dev Biol. 2021;9:637725.
22. Bárcia RN, Santos JM, Teixeira M, et al. Umbilical cord tissue-derived mesenchymal stromal cells maintain immunomodulatory and angiogenic potencies after cryopreservation and subsequent thawing. Cytotherapy. 2017;19(3):360-370.
23. Marquez-Curtis LA, Elliott JA. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects: Update from 2015 review. Cryobiology. 2024;115:104856.
24. Mukai T, Tojo A, Nagamura-Inoue T. Mesenchymal stromal cells as a potential therapeutic for neurological disorders. Regen Ther. 2018;9:32-37.
25. Skiles ML, Marzan AJ, Brown KS, Shamonki JM. Comparison of umbilical cord tissue-derived mesenchymal stromal cells isolated from cryopreserved material and extracted by explantation and digestion methods utilizing a split manufacturing model. Cytotherapy. 2020;22(6):581-591.
26. Guan YT, Xie Y, Li DS, et al. Comparison of biological characteristics of mesenchymal stem cells derived from the human umbilical cord and decidua parietalis. Mol Med Rep. 2019;20(1):633-639. doi:10.3892/mmr.2019.10286.
27. Zhao L, Chen S, Yang P, Cao H, Li L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: Prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):1-13. doi:10.1186/s13287-019-1287-9.
28. Le Thi Bich P, Nguyen Thi H, Dang Ngo Chau H, et al. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: A pilot clinical study. Stem Cell Res Ther. 2020;11(1):1-14. doi:10.1186/s13287-020-1583-4.
29. Kol A, Wood JA, Carrade Holt DD, et al. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses. Stem Cell Res Ther. 2015;6(1):1-9.
30. Marquez-Curtis LA, Elliott JA. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects: Update from 2015 review. Cryobiology. 2024;115:104856. doi:10.1016/j.cryobiol.2024.104856.
31. Baba K, Yamazaki Y, Sone Y, et al. An in vitro long-term study of cryopreserved umbilical cord blood-derived platelet-rich plasma containing growth factors—PDGF-BB, TGF-β, and VEGF. J Craniomaxillofac Surg. 2019;47(5):668-675.